Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Enzalutamide (Primary) ; Goserelin; Leuprorelin
- Indications Prostate cancer
- Focus Adverse reactions
- 25 Jul 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
- 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated